Anthrax - Pipeline Review, H2 2013 - New Market Research Report

Global Markets Direct's, 'Anthrax - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anthrax, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anthrax. Anthrax - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

Full Report Details at
- http://www.fastmr.com/prod/769114_anthrax_pipeline_review_h2_2013.aspx?afid=303

* A snapshot of the global therapeutic scenario for Anthrax.
* A review of the Anthrax products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Anthrax pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Anthrax.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Anthrax pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Bristol-Myers Squibb Company, Aradigm Corporation, Bavarian Nordic A/S, Emergent BioSolutions Inc., Cangene Corporation, The Medicines Company, Astex Pharmaceuticals, Inc., Oragenics, Inc., Soligenix, Inc., Elusys Therapeutics, Inc., Green Cross Corporation, Panacea Biotec Limited, Summit Corporation plc, Evolva SA, MacroGenics, Inc., Vaxin, Inc., Phage Pharmaceuticals, Inc., NanoBio Corporation, Immunovaccine, Inc., iBio, Inc., Cellceutix Corporation, Tetraphase Pharmaceuticals Inc., Aparna Biosciences Corp., PaxVax, Pfenex Inc., SelectX Pharmaceuticals, Inc., Revivicor, Inc., Procarta Biosystems Ltd, Innovative Biologics, Inc., PsiOxus Therapeutics, Ltd., Conkwest, Inc., Greffex, Inc.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Staphylococcus Aureus Infections - Pipeline Review, H2 2013
- Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013
- Allergic Asthma - Pipeline Review, H2 2013
- Influenza - Pipeline Review, H2 2013
- Alzheimer's Disease - Pipeline Review, H2 2013